Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998048789) PHARMACEUTICAL COMPOSITIONS OF ARGLABIN AND ARGLABIN DERIVATIVES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/048789 International Application No.: PCT/US1998/007989
Publication Date: 05.11.1998 International Filing Date: 22.04.1998
Chapter 2 Demand Filed: 23.11.1998
IPC:
A61K 31/343 (2006.01) ,A61K 31/365 (2006.01) ,A61K 31/475 (2006.01) ,A61K 31/505 (2006.01) ,A61K 31/5377 (2006.01) ,A61K 31/675 (2006.01) ,A61K 33/24 (2006.01) ,A61K 45/06 (2006.01) ,C07D 307/93 (2006.01) ,C07D 493/04 (2006.01) ,C07D 493/10 (2006.01) ,C07D 493/20 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
343
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
365
Lactones
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
475
having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5377
not condensed and containing further heterocyclic rings, e.g. timolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
66
Phosphorus compounds
675
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33
Medicinal preparations containing inorganic active ingredients
24
Heavy metals; Compounds thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
307
Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
77
ortho- or peri-condensed with carbocyclic rings or ring systems
93
condensed with a ring other than six-membered
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
10
Spiro-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
12
in which the condensed system contains three hetero rings
20
Spiro-condensed systems
Applicants:
PARACURE, INC. doing business as KAZAK-PARACURE [US/US]; Suite 403 4665 Haygood Road Virginia Beach, VA 23455, US
Inventors:
ADEKENOV, Sergazy M.; KZ
Agent:
MATNEY, W., Jackson, Jr.; Milbank, Tweed, Hadley & McCloy Suite 1100 1825 Eye Street, N.W. Washington, D.C. 20006, US
Priority Data:
08/934,22819.09.1997US
08/934,22919.09.1997US
08/934,47119.09.1997US
60/051,68103.07.1997US
970397126.04.1997KZ
Title (EN) PHARMACEUTICAL COMPOSITIONS OF ARGLABIN AND ARGLABIN DERIVATIVES
(FR) COMPOSITIONS PHARMACEUTIQUES CONSTITUEES D'ARGLABINE ET DE DERIVES D'ARGLABINE
Abstract:
(EN) Pharmaceutical compositions containing arglabin and arglabin derivatives are described. The compositions can be in unit dosage form and are useful for the treatment of cancer in humans. Compositions and kits containing a first chemotherapeutic agent that includes arglabin or a derivative thereof and a second chemotherapeutic agent are also described. The compositions and kits are effective for treating cancer in a human patient. The invention also provides various derivatives of arglabin, effective for suppressing tumor growth in mammals.
(FR) L'invention concerne des compositions pharmaceutiques contenant de l'arglabine et des dérivés d'arglabine. Lesdites compositions peuvent se présenter sous forme de dose unitaire et sont utiles pour le traitement du cancer chez les humains. L'invention porte aussi sur des kits contenant un premier agent contenant de l'arglabine ou un dérivé de celle-ci et un deuxième agent chimiothérapeutique. Les compositions et les kits sont efficaces pour le traitement du cancer chez un patient humain. L'invention porte encore sur divers dérivés de l'arglabine, efficaces pour la suppression de la croissance tumorale chez les mammifères.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
MXPA/a/1999/009817KR1020010020318EP0996441US5902809US6080741US6020365
US6262110US6429203US6693127US6770673JP2002509532 CA2287318
AU1998071418AU2002301519